AUA 2018 - The largest gathering of urologists in the world

AUA 2018: Is Prostate Cancer Screening and Risk Stratification Moving Beyond the PSA Test?

Truckee, CA (UroToday.com) -- New diagnostic tests for prostate cancer, as well as new information about the impact of the U.S. Preventive Services Task Force recommendations on prostate cancer screening will be presented this year during the 113th Annual Meeting of the American Urological Association (AUA). Four studies highlighting these topics will be shared during a special press conference on May 18 at 8:30 a.m. (PT). Stacy Loeb, MD, AUA spokesperson and assistant professor of urology and population health at New York University will moderate this session for media.

AUA 2018: Cleveland Clinic-led Study Finds that More than 40 Percent of Prostate Biopsies Could Have Been Avoided with New Blood Test

Truckee, CA (UroToday.com) -- A multi-center study that validates the clinical performance of IsoPSA – a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard prostate-specific antigen (PSA) – will be presented during a special press conference at the 13^th Annual Meeting of the American Urological Association (AUA) on May 18 in San Francisco.

AUA 2018: Primary Adrenal Malignancy: Insights into the Epidemiology of a Rare Histological Subset

San Francisco, CA (UroToday.com) Renal cell carcinoma (RCC) has traditionally been surgically managed. Extirpative surgery, either radical nephrectomy (RN) or partial nephrectomy (PNx), remains the standard of care for localized disease. Targeted therapies (TT), including tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, have become a cornerstone of RCC therapy, specifically for metastatic RCC, demonstrating extended progression-free survival. While the efficacy of targeted therapies is well established for metastatic RCC, its role as an adjuvant therapy is less clear.

AUA 2018: Augmenix, Inc. Announces Exciting Plans for the 2018 American Urological Association Meeting in San Francisco

Truckee, CA (UroToday.com) -- Augmenix, Inc. is pleased to announce that they will be exhibiting at this year’s American Urological Association meeting in San Francisco, California. Located at Booth 6251 Hall D, the company will be featuring their leading product, SpaceOAR® hydrogel, which is used in patients receiving radiation therapy for prostate cancer. Attendees of the AUA meeting are invited to visit the exhibit to learn about the latest developments that make SpaceOAR hydrogel the #1 rectal spacer for prostate cancer radiotherapy worldwide.

AUA 2018: Photocure to Present New Data on Cysview® at the 2018 American Urological Association Annual Meeting

Truckee, CA (UroToday.com) -- Photocure ASA announced that Photocure will be exhibiting Blue Light Cystoscopy (BLC™) with Cysview in Booth 1825, during the American Urological Association Meeting (AUA 2018) in San Francisco, CA.

New data on Cysview will be presented in at least three posters, of which two are on registry studies using real-world longitudinal data, a plenary session on Patient Reported Outcomes and during the Bladder Cancer Surgical Technique session. Dr. James McKiernan will present on "Enhanced Cystoscopy: BLC – TURBT + Surveillance Video".

AUA 2018: Results from Interim Analysis of Pivotal Phase 3 Trial of UGN-101 for Non-Surgical Treatment of Upper Tract Urothelial Cancer

Truckee, CA (UroToday.com) -- UroGen Pharma Ltd., a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced a new data presentation from an interim analysis of the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101 (MitoGel™), an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC). The full interim analysis will be presented on Monday, May 21, 2018 in an oral presentation during the plenary session at the 113th American Urological Association's (AUA) Annual Meeting in San Francisco.

Late-Breaker Presentation for NOCTIVA™ Accepted for the 2018 American Urological Association Meeting

Truckee, CA (UroToday.com) -- Avadel Pharmaceuticals plc announced that new data from NOCTIVA’s pivotal Phase III clinical trials will be presented at the American Urological Association (AUA) 2018 annual meeting in San Francisco as a late-breaking presentation feature in the Next Frontiers plenary session. The presentation will share new data on extending the time to first uninterrupted sleep in elderly patients with nocturia following treatment with AV002 (NOCTIVA).

Page 52 of 52

AUA 2018 - The largest gathering of urologists in the world

Free Daily and Weekly newsletters offered by content of interest

Login